在临床实践中使用己酸17α-羟孕酮来影响复发性早产的发生率。
Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice.
作者信息
Rebarber Andrei, Fox Nathan S, Klauser Chad K, Istwan Niki B, Rhea Debbie J, Stanziano Gary J, Saltzman Daniel H
机构信息
Maternal Fetal Medicine Associates, New York, NY 10029, USA.
出版信息
J Matern Fetal Neonatal Med. 2010 Oct;23(10):1139-42. doi: 10.3109/14767051003615418.
OBJECTIVE
Evaluation of an outpatient 17 α-hydroxyprogesterone caproate (17P) administration programme.
METHODS
A retrospective analysis of data collected from patients with a history of preterm birth (PTB) and current singleton gestation enrolled between 16.0 and 20.9 weeks' gestational age (GA) for weekly outpatient 17P administration and nursing assessment between 7/2004 and 12/2007 was conducted (n=3139).
RESULTS
The population was mostly white (50.3%), 18-35 years old (77.7%), and married (67.0%). Median GA at 17P initiation and stop was 17.4 (16.0, 20.9) weeks and 35.1 (18.6, 37.4) weeks. Mean injections per patient were 16.5±4.9, at an interval of 7.2 days. Median GA at delivery was 37.3 (18.6, 44.0) weeks. Rate of recurrent spontaneous PTB was 29.8%, with 15.5% and 7.0% with PTB at <35 and <32 weeks.
CONCLUSIONS
This represents the largest cohort reported to date of patients prescribed 17P therapy in clinical practice to prevent recurrent spontaneous PTB.
目的
评估门诊己酸羟孕酮（17P）给药方案。
方法
对2004年7月至2007年12月期间纳入的有早产史且当前为单胎妊娠、孕龄在16.0至20.9周之间的患者进行回顾性数据分析，这些患者每周接受门诊17P给药及护理评估（n = 3139）。
结果
研究人群大多为白人（50.3%），年龄在18 - 35岁之间（77.7%），已婚（67.0%）。开始和停止使用17P时的孕龄中位数分别为17.4（16.0，20.9）周和35.1（18.6，37.4）周。每位患者平均注射次数为16.5±4.9次，间隔时间为7.2天。分娩时的孕龄中位数为37.3（18.6，44.0）周。复发性自发性早产率为29.8%，其中孕35周前早产率为15.5%，孕32周前早产率为7.0%。
结论
这是迄今为止临床实践中报告的接受17P治疗以预防复发性自发性早产患者的最大队列。
Zotero 插件